The company said it will apply for U.S. approval for the treatment for a type of advanced blood cancer by the end of the year.
The study tested three dose levels of liso-cel in the 269 patients with relapsed or refractory large B-cell lymphoma. The data marks a win for Bristol-Myers after its purchase of Celgene met resistance from some investors who thought that it was overpaying for the cancer-focused biotech. Celgene had forecast annual sales reaching $3 billion for the immunotherapy. If approved, it would lessen some of Bristol-Myers’ dependence on its immunotherapy Opdivo, which has faced stiff competition from Merck & Co’s market leading rival drug Keytruda.
Belgique Dernières Nouvelles, Belgique Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
La source: SABC News Online - 🏆 32. / 51 Lire la suite »
La source: SABC News Online - 🏆 32. / 51 Lire la suite »